MarkCWaltersMD

Pediatric Hematology & Oncology • Oakland, CA

Professor of Pediatrics, UCSF and Jordan Family Director, BMT Program, UCSF Benioff Children's Hosp, Oakland

Join to view full profile

Dr. Walters is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Walters' full profile

Already have an account?

Office
747 52nd St
Dept Of Hematology/Oncology
Oakland, CA 94609
Phone+1 510-428-3374

Fax+1 510-601-3916

Summary

Dr. Mark Walters is a pediatric hematologist/oncologist in Oakland, CA and is affiliated with multiple hospitals in the area, including UCSF Benioff Children's Hospital Oakland, Alta Bates Summit Medical Center, John Muir Medical Center, Walnut Creek, and Queen of the Valley Medical Center. He received his medical degree from University of California San Diego School of Medicine and has been in practice 32 years. He is experienced in sickle-cell anemia, graft-versus-host disease, histocompatibility testing, cord blood stem cell transplantation, and pediatric bone marrow transplantation. He is leading a NIH/CIRM supported sickle gene editing project and participating in gene therapy clinical trials for thalassemia and sickle cell disease.

Education & Training

University of WashingtonFellowship, Pediatric Hematology/Oncology, 1988 - 1992
University of California San Diego School of MedicineClass of 1985

Certifications & Licensure

CA State Medical License 1999 - 2025
NV State Medical License 2007 - 2023
KY State Medical License 2007 - 2021
MA State Medical License 2007 - 2020
RI State Medical License 2009 - 2020
NJ State Medical License 2007 - 2019
PA State Medical License 2007 - 2010
WA State Medical License 1986 - 2000
American Board of Pediatrics Pediatric Hematology-Oncology
Join now to see all

Clinical Trials

Bone Marrow Transplantation in Treating Children With Sickle Cell Disease Start of enrollment: 1999 Dec 01
Completed
Phase 1, Phase 2
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia Start of enrollment: 1999 Jan 01
Completed
Phase 2
Induction of Stable Chimerism for Sickle Cell Anemia Start of enrollment: 2001 Aug 01
Completed
Phase 2
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) Start of enrollment: 2006 Dec 01
Completed
Phase 3
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia Start of enrollment: 2007 Feb 01
Completed
Phase 2
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders Start of enrollment: 2006 Jun 01
Completed
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Roles: Principal Investigator, Contact
Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease Start of enrollment: 2012 Jan 01
Active, not recruiting
Phase 2
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant Start of enrollment: 2013 Mar 21
Completed
Phase 3
Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease Start of enrollment: 2012 Mar 01
Completed
Phase 2
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503) Start of enrollment: 2016 Nov 01
Completed
Phase 2
STRIDE Biorepository Start of enrollment: 2017 Mar 13
Recruiting
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507) Start of enrollment: 2017 Oct 03
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease.
Tami D John, Mark C Walters, Hemalatha G Rangarajan, Mahvish Q Rahim, Christopher McKinney
Blood Advances. 2024-12-10
8 citations
Access to Chimeric Antigen Receptor T Cell Clinical Trials in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult Acute Lymphobastic ...
Anurekha G Hall, Lena E Winestone, Erin M Sullivan, Qian Wu, Adam J Lamble
Transplantation and Cellular Therapy. 2023-06-01
8 citations
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.
Mary Eapen, Ruta Brazauskas, David A Williams, Mark C Walters, Andrew St Martin
Journal of Clinical Oncology. 2023-04-20

Journal Articles

The Safety and Efficacy of Clofarabine in Combination with High-Dose Cytarabine and Total Body Irradiation Myeloablative Conditioning and Allogeneic Stem Cell Transpla...
Stacey Zahler, Mitchell S Cairo, Jennifer Krajewski, M Fevzi Ozkaynak, Alexandra C Cheerva, Theodore B Moore, Alfred P Gillio, Mark C Walters, Nature

Abstracts/Posters

Northstar-2: Updated Safety and Efficacy Analysis of Lentiglobin Gene Therapy in Patients with Transfusion-Dependent _-Thalassemia and Non-_0/_0 Genotypes
Mark C. Walters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy
Mark C. Walters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent B...
Mark C. Walters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Pr...
Mark C. Walters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Prepa...
Mark C. Walters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study
Mark C. Walters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease: BMT CTN Protocol 1507
Mark C. Walters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent _-Thalassemia in the Northstar (HGB-204) Study
Mark C. Walters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Advancing Science in Sickle Cell Disease: Implications for the Future of Care
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia Following Completion of the Northstar Hgb-204 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Advancing the Treatment of Hemoglobinopathies: Gene Therapy for Beta Thalassemia and Sickle Cell Disease
60th American Society of Hematology Annual Meeting - 11/30/2018
Sickle Cell Disease Forum: Innovation in Drug Development and Emerging Science
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

Novel Gene Therapy Trial for Sickle Cell Disease LaunchesNovember 22nd, 2024
Cell and Gene Therapies Symposium Open to PublicOctober 24th, 2024
Why Gene Therapy for Sickle Cell Is Slow to Catch on with PatientsSeptember 28th, 2024
Join now to see all

Grant Support

Hematopoietic Cell Therapy For Young Adults With Severe Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2011
Northern California Consortium For Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2006–2008
Induction Of Stable Chimerism For Sickle Cell AnemiaNational Heart, Lung, And Blood Institute2001–2004
Mechanisms Of Globin Gene SilencingNational Heart, Lung, And Blood Institute1998–1999
Globin Gene Regulation By GATA-1 And ChromatinNational Heart, Lung, And Blood Institute1998
Mechanisms Of Erythroid Gene ExpressionNational Heart, Lung, And Blood Institute1994–1997